Home › Funds › Fairmount Funds Management LLC › CBIO

Fairmount Funds Management LLC position in CBIO

CRESCENT BIOPHARMA INC. · Health Care

Fairmount Funds Management LLC reported holding 2,747,866 shares of CBIO (CRESCENT BIOPHARMA INC.) in its Q2 2026 13F filing — a position valued at US$49.5M, representing 3.27% of its reported portfolio and ranking #9 among its reported holdings. Fairmount Funds Management LLC has disclosed CBIO holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)2.75M sh
Reported value held$49.46M
Portfolio Weight3.27%
First reportedQ2 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Fairmount Funds Management LLC's CBIO position evolved

Fairmount Funds Management LLC first disclosed a stake in CBIO in Q2 2025 at 1,387,866 shares (US$22.4M). The position peaked in Q1 2026 at 2,747,866 shares, worth US$50.5M. Across 5 filings, Fairmount Funds Management LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 2,747,866 shares valued at US$49.5M. Notable position changes include a 98% increase in Q4 2025 (shares rose 55% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 1.39M $22.40M New
Q3 2025 1.39M $16.50M Hold
Q4 2025 2.75M $32.59M Add
Q1 2026 2.75M $50.48M Hold
Q2 2026 2.75M $49.46M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CBIO and 13F data

CBIO (CRESCENT BIOPHARMA INC.) is a Health Care company. 71 other funds we track also report a position in CBIO — the largest reported positions include BVF INC/IL (US$49.5M), Venrock Adviser, LLC (US$38.4M), Logos Global Management LP (US$34.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CBIO

All CBIO fund holders →

FAQ

How long has Fairmount Funds Management LLC held CBIO?

Fairmount Funds Management LLC has disclosed CBIO holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is Fairmount Funds Management LLC's current position in CBIO?

As of Q2 2026, Fairmount Funds Management LLC holds 2.75M shares of CBIO (CRESCENT BIOPHARMA INC.), valued at $49.46M, representing 3.27% of its reported portfolio and ranking #9.

Has Fairmount Funds Management LLC been buying or selling CBIO?

In the latest 13F filing (Q2 2026), Fairmount Funds Management LLC held unchanged its position in CBIO. The position peaked in Q1 2026 at 2.75M shares.

Which other funds hold CBIO?

Other major institutional holders of CBIO include BVF INC/IL, Venrock Adviser, LLC, Logos Global Management LP, among 71 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.